Oscar Health (OSCR) EBITDA (2020 - 2026)

Oscar Health (OSCR) has 7 years of EBITDA data on file, last reported at $60.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 79.6% year-over-year to $60.6 million; the trailing twelve-month figure through Mar 2026 stood at -$165.9 million (down 143.87% YoY), and the FY2025 full-year result was -$396.4 million, down 313.41% from the prior year.
• EBITDA for Q1 2026 stood at $60.6 million, up from -$333.7 million in the prior quarter.
• Across five years, EBITDA topped out at $297.1 million in Q1 2025 and bottomed at -$355.5 million in Q4 2023.
• The 5-year median for EBITDA is $36.1 million (2023), against an average of -$17.3 million.
• The widest annual swing landed in 2022, when EBITDA plunged 4675.25%; it then surged 5073.03% in 2023.
• A 5-year view of EBITDA shows it stood at -$222.5 million in 2022, then plunged by 59.8% to -$355.5 million in 2023, then soared by 94.58% to -$19.3 million in 2024, then slumped by 1632.22% to -$333.7 million in 2025, then soared by 118.16% to $60.6 million in 2026.
• The last three EBITDA figures came in at $60.6 million (Q1 2026), -$333.7 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.

Peer Comparison